查看文章

Tofacitinib is a JAK inhibitor that decreases cytokine production. In a woman with autoimmune colitis from the administration of pembrolizumab to treat her cancer, tofacitinib induced remission in 5 days, after glucocorticoids, infliximab, and vedolizumab had been ineffective. The cancer responded to immunotherapy, and the autoimmune complication resolved with tofacitinib.